Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Scientists Identify Five Drug Compounds That Completely Stop SARS-CoV-2 Replication by Interrupting Communication Pathways in Host Cells

By HospiMedica International staff writers
Posted on 27 Aug 2020
Researchers have patented their technique of inhibiting cellular growth factor signaling to stop the SARS-CoV-2 from replicating and treat COVID-19, according to a report by Drug Target Review.

A team of biochemists and virologists from the Goethe University Frankfurt (Frankfurt, Germany) found that SARS-CoV-2 requires growth factor receptor cell signaling pathways for replication and have patented their method of interrupting these pathways to treat COVID-19.

Previous studies have found that the activity of proteins involved in these signaling cascades is generally controlled by the attachment or removal of phosphate groups. More...
The addition or removal of a phosphate group on a protein triggers the propagation of such signals which usually target the cell nucleus, leading to the expression or silencing of specified genes. The researchers documented how these communication pathways are impacted when cells are infected by the SARS-CoV-2 virus. In order to document the signals, the team analyzed all the proteins carrying a phosphate group at a given moment in time, also known as the phosphoproteome.

The team found that SARS-CoV-2 infection activated growth factor receptor signaling (and its downstream signaling cascades). With the help of drug-protein network analysis, the researchers also demonstrated inhibition of growth factor receptor downstream signaling using five approved drug compounds that prevented SARS-CoV-2 replication in cells. This was assessed by cytopathic effect, viral dsRNA production and viral RNA release into the supernatant, according to the Drug Target Review report.

Dr. Christian Münch from the Institute of Biochemistry II at Goethe University told Drug Target Review, “The signaling pathways of the growth factors can be blocked precisely at the point where the signal from outside the cell docks onto a signal receiver - a growth factor receptor. There are, however, a number of very effective cancer drugs that interrupt growth factor signaling pathways slightly further down the cascade, through which the signals of different growth factor receptors are blocked. We have tested five of these substances on our cells, and all five led to a complete stop of SARS-CoV-2 replication.”

Related Links:
Goethe University Frankfurt
University Hospital Frankfurt



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.